What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published
Group 2336.png

 

Valsartan Range

 

Welcome to the HTN Product section of the Egypt HCP Portal. This section provides comprehensive information about Valsartan hypertension treatment, clinical trials, and more details to support healthcare professionals. 

Valsartan has played a pivotal role in the management of hypertension. Explore how Valsartan supports blood pressure control, cardiovascular protection, and long-term patient outcomes through evidence-based data and real-world applications. 

This overview page presents key highlights on Valsartan portfolio.

Group 2425.png
Frame 427318509.png
Frame 427318501.png
Frame 427318502.png
Frame 427318503.png
Frame 427318504.png
Frame 427318868.png
Frame 427318510.png
Frame 427318505.png
Frame 427318506.png
Frame 427318507.png
Frame 427318508.png

Nobel prize in Valsartan synthesis12

Frame.png

2010 Nobel Prize in Chemistry on "Palladium 
Catalyzed Cross Couplings in Organic Synthesis this 
was later used in the Valsartan molecule synthesis.12

Frame 427318512.png
Frame 427318514.png
Frame 427318515.png
Frame 427318516.png

Watch How Valsartan Controls Blood Pressure

HTN: Hypertension, HCP: Healthcare professionals.

Valsartan MOA video VIDEO

The complete Valsartan approach

Frame 427318870.png

Protection

Protection
See more details
Hide details
Frame 427318871.png

Guidelines

Guidelines
See more details
Hide details
Frame 427318872.png

24-hour control

24-hour control
See more details
Hide details
Frame 427318873.png

Co-Tareg®

Co-Tareg®
See more details
Hide details
Frame 427318875.png

Exforge®

Exforge®
See more details
Hide details
Frame 427318890.png

Exforge HCT®

Exforge HCT®
See more details
Hide details

References

  1. Egyptian drug authority Tareg approved leaflet; approval date: 26/10/2020. 

  2. European medicine agency. Diovan referral. Available at: https://www.ema.europa.eu/en/medicines/human/referrals/diovan-1; last accessed: 13/7/2025. 

  3. Lacourcière Y, Poirier L, Hebert D, Assouline L, Stolt P, Rehel B, Khder Y. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clinical therapeutics. 2005 Jul 1;27(7):1013-21. 

  4. Destro M, Luckow A, Samson M, Kandra A, Brunel P. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS Study. Journal of the American Society of Hypertension. 2008 Jul 1;2(4):294-302. 

  5. Calhoun DA, Crikelair NA, Yen J, Glazer RD. Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: secondary analyses evaluating efficacy and safety. Advances in therapy. 2009 Nov;26(11):1012-23. 

  6. Sison J, Assaad-Khalil SH, Najem R, Kitchlew AR, Cho B, Ueng KC, Shete A, Knap D. Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: the EXCITE study. Current medical research and opinion. 2014 Oct 1;30(10):1937-45. 

  7. Karpov Y, Dongre N, Vigdorchik A, Sastravaha K. Amlodipine/valsartan single-pill combination: a prospective, observational evaluation of the real-life safety and effectiveness in the routine treatment of hypertension. Advances in therapy. 2012 Feb;29(2):134-47. 

  8. El-Etriby AM, Rakha S. Efficacy and safety of amlodipine/valsartan/hydrochlorothiazide single pill combination in Egyptian patients with hypertension uncontrolled on any dual therapy: an observational study. Current Medical Research and Opinion. 2020 Apr 2;36(4):537-44. 

  9. Assaad-Khalil SH, Nashaat N. Real-life effectiveness and safety of amlodipine/valsartan single-pill combination in patients with hypertension in Egypt: results from the EXCITE study. Drugs-Real World Outcomes. 2016 Sep;3(3):307-15. 

  10. Nixon RM, Müller E, Lowy A, Falvey H. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta‐analytical approach. International journal of clinical practice. 2009 May;63(5):766-75. 

  11. Abts M, Claus V, Lataster M. Blood pressure control with valsartan and hydrochlorothiazide in clinical practice: The MACHT Observational Study. Blood Pressure. 2006 Jan 1;15(sup1):27-32. 

  12. Nagendrappa G, Sunil Kumar YC. The 2010 chemistry nobel prize: Pd (0)-catalyzed organic synthesis. Resonance. 2011 Feb;16(2):152-64. 

  13. Hermida RC, Calvo C, Ayala DE, Domínguez MJ, Covelo M, Fernández JR, Mojón A, López JE. Administration time–dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension. 2003 Sep 1;42(3):283-90. 

  14. Egyptian drug authority Co-tareg approved leaflet; approval date: 8/5/2025. 

  15. Egyptian drug authority Exforge approved leaflet; approval date: 4/5/2025. 

  16. Egyptian drug authority Exforge HCT approved leaflet; approval date: 4/5/2025.

Approved by Egyptian Drug Authority: HF0082OA4758/102025. Invalidation date: 14/10/2027.
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg.

Valsartan QR.jpeg

HF0082OA4758/102025 14/10/2027

 

        

Adverse Events Reporting

We encourage using the following Electronic reporting tool for reporting into the safety database directly:
If the electronic reporting tool is not working - please use the following: https://www.report.novartis.com
1 - Generic Mailbox: [email protected]
2 - CISCO: +20 2 2 2861000: Press 3 for Adverse Events Reporting